The transthyretin (TTR) amyloidoses
are a group of degenerative
diseases caused by TTR aggregation, requiring rate-limiting tetramer
dissociation. Kinetic stabilization of TTR, by preferential binding
of a drug to the native tetramer over the dissociative transition
state, dramatically slows the progression of familial amyloid polyneuropathy.
An established method for quantifying the kinetic stability of recombinant
TTR tetramers in buffer is subunit exchange, in which tagged TTR homotetramers
are added to untagged homotetramers at equal concentrations to measure
the rate at which the subunits exchange. Herein, we report a subunit
exchange method for quantifying the kinetic stability of endogenous
TTR in human plasma. The subunit exchange reaction is initiated by
the addition of a substoichiometric quantity of FLAG-tagged TTR homotetramers
to endogenous TTR in plasma. Aliquots of the subunit exchange reaction,
taken as a function of time, are then added to an excess of a fluorogenic
small molecule, which immediately arrests further subunit exchange.
After binding, the small molecule reacts with the TTR tetramers, rendering
them fluorescent and detectable in human plasma after subsequent ion
exchange chromatography. The ability to report on the extent of TTR
kinetic stabilization resulting from treatment with oral tafamidis
is important, especially for selection of the appropriate dose for
patients carrying rare mutations. This method could also serve as
a surrogate biomarker for the prediction of the clinical outcome.
Subunit exchange was used to quantify the stabilization of WT TTR
from senile systemic amyloidosis patients currently being treated
with tafamidis (20 mg orally, once daily). TTR kinetic stability correlated
with the tafamidis plasma concentration.
Increasing evidence supports the hypothesis that soluble misfolded protein assemblies contribute to the degeneration of post-mitotic tissue in amyloid diseases. However, there is a dearth of reliable non-antibody based probes for selectively detecting oligomeric aggregate structures circulating in plasma or deposited in tissues, making it difficult to scrutinize this hypothesis in patients. Hence, understanding the structure-proteotoxicity relationships driving amyloid diseases remains challenging, hampering the development of early diagnostic and novel treatment strategies. Here, we report peptide-based probes that selectively label misfolded transthyretin (TTR) oligomers circulating in the plasma of TTR hereditary amyloidosis patients exhibiting a predominant neuropathic phenotype. These probes revealed that there are much fewer misfolded TTR oligomers in healthy controls, in asymptomatic carriers of mutations linked to amyloid polyneuropathy, and in patients with TTR-associated cardiomyopathies. The absence of misfolded TTR oligomers in the plasma of cardiomyopathy patients suggests that the tissue tropism observed in the TTR amyloidoses is structure based. Misfolded oligomers decrease in TTR amyloid polyneuropathy patients treated with disease-modifying therapies (tafamidis or liver transplant-mediated gene therapy). In a subset of TTR amyloid polyneuropathy patients, the probes also detected a circulating TTR fragment that disappeared after tafamidis treatment. Proteomic analysis of the isolated TTR oligomers revealed a specific patient associated-signature comprised of proteins that likely associate with the circulating TTR oligomers. Quantification of plasma oligomer concentrations using peptide probes could become an early diagnostic strategy, a response-to-therapy biomarker, and a useful tool for understanding structure-proteotoxicity relationships in the TTR amyloidoses.
Conflict of interest: Conflict of interest statement: JWK discovered tafamidis at the Scripps Research Institute; is a shareholder of FoldRx (Pfizer), the companies that developed tafamidis into a drug; and he and ETP receive royalty payments from tafamidis sales. JWK is a paid consultant for the Pfizer Orphan and Rare Diseases organization. Pfizer supported JWK's expenses with travel and accommodation for scientific meetings. TC is a past and current investigator in clinical trials sponsored by FoldRx, Pfizer, Alnylam, Ionis, and Prothena; these trials were paid per protocol to Centro Hospitalar do Porto. TC is a consultant for Pfizer, Alnylam, Ionis, and Prothena. TC has spoken on behalf of Pfizer, Alnylam, Glaxo, and Prothena at scientific meetings and received financial compensation. Pfizer, Alnylam, Ionis, and Biogen supported TC's expenses with travel, accommodation, and registration for scientific meetings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.